La catena delle opzioni mostra i dati chiave delle opzioni azionarie di PTC Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per PTC Therapeutics..

PTC Therapeutics (NASDAQ:PTCT) Azioni, Catena delle Opzioni

PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

PTC Therapeutics Inc

News

PTCT

PTC Therapeutics Announced That The U.S. Food And Drug Administration Has Accepted For Review The Resubmission Of The New Drug Application For Translarna For The Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy

The opinion will now be reviewed by the European Commission (EC) which is expected to decide on opinion adoption in approximately 67 days.
&quot;CHMP again based its decision on the results of the primary analysis subpopulation of Study 041 instead of the totality of evidence for Translarna. That evidence includes data across three placebo-controlled trials and our STRIDE registry that demonstrates consistent short and long-term efficacy as well as safety supportive of continued authorization. In addition, the CHMP opinion is clearly against the expressed wishes of physicians, patients and families throughout&nbsp;Europe,&quot; said&nbsp;Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc.

PTC Therapeutics Says CHMP Of European Medicines Agency Maintained Its Negative Opinion On Renewal Of Conditional Marketing Authorization Of Translarna For Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy

Biotech

General

PTC Therapeutics Reports FDA Sets Target Regulatory Action Date For Sepiapterin and Lancet Publication Of Phase 3 Trial Results

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and raises the price target from $32 to $45.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $45

Baird analyst Joel Beatty reiterates PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform and maintains $44 price target.

Reiteration

Baird Reiterates Outperform on PTC Therapeutics, Maintains $44 Price Target

WIIM

PTC Therapeutics shares are trading higher after the company announced its Vatiquinone Friedreich Ataxia program met its endpoint for two FA long-term extension studies. Also, PTC has recently aligned with the FDA on key aspects of the planned NDA submission.

PTC Therapeutics Announces Updates On Vatiquinone Friedreich Ataxia Program; Says Pre-Specified Endpoint For Two FA Long-Term Extension Studies Was Met, Says Co. Recently Aligned With FDA On Key Aspects On Planned NDA Submission

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Sector Perform and raises the price target from $32 to $34.

RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $34

PTC Therapeutics Announces FDA Acceptance For Filing Of NDA For Sepiapterin For Pediatric And Adult Phenylketonuria Patients

FDA Grants Fast Track Designation To PTC Therapeutics' PTC518 Program For Huntington's Disease, Highlighting Its Potential As A Disease-Modifying Therapy

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and maintains $64 price target.

Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target

Baird analyst Joel Beatty initiates coverage on PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform rating and announces Price Target of $44.

Initiation

Baird Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces Price Target of $44

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $62 to $64.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $64

Barclays analyst Gena Wang maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and raises the price target from $25 to $31.

Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $31

PTC Updates Full Year 2024 Financial Guidance:&nbsp;
<ul>
<li>PTC anticipates total revenues for full year 2024 to be between $700 million and $750 million.</li>
<li>PTC anticipates GAAP R&amp;D and SG&amp;A expenses for full year 2024 to be between $740 million and $835 million, including expected R&amp;D expense milestone payments of up to $65 million.</li>
<li>PTC anticipates Non-GAAP R&amp;D and SG&amp;A expenses for full year 2024 to be between $660 million and $755 million, including expected R&amp;D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.</li>
<li>PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&amp;D operating expenses. As of June 30, 2024, $35 million in milestones have been achieved, of which $15 million has been recorded as R&amp;D operating expenses and $20 million as contingent consideration payable.</li>
</ul>

Guidance

PTC Sees FY24 Revenue $700M-$750M Vs $749M Estimate

PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.19) by 8.4 percent. The company reported quarterly sales of $186.704 million which beat the analyst consensus estimate of $185.319 million by 0.75 percent. This is a 12.68 percent decrease over sales of $213.808 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

PTC Therapeutics Q2 2024 GAAP EPS $(1.29) Misses $(1.19) Estimate, Sales $186.704M Beat $185.319M Estimate

PTC Therapeutics Submits Sepiapterin NDA To FDA For Treatment Of Pediatric And Adult Phenylketonuria (PKU) Patients

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and maintains $62 price target.

Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $62 Price Target

Robert W. Baird analyst Joel Beatty has maintained their bullish stance on PTCT stock, giving a Buy rating today. Joel Beatty's rating is based on ...

Positive Clinical Trials and FDA Advancements Bolster Buy Rating for PTC Therapeutics

In a report released today, Paul Choi from Goldman Sachs maintained a Sell rating on PTC Therapeutics (PTCT – Research Report), with a price target...

Sell Rating on PTC Therapeutics Amid Regulatory Uncertainties and Efficacy Concerns

Analysts fell to the sidelines weighing in on PTC Therapeutics (PTCT – Research Report) and Accolade (ACCD – Research Report) with neutral ratings,...

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Accolade (ACCD)

Gena Wang, an analyst from Barclays, maintained the Hold rating on PTC Therapeutics (PTCT – Research Report). The associated price target remains t...

Balancing Hope and Caution: Holding PTC Therapeutics Amid Vatiquinone's Mixed Clinical Results

Leerink Partners analyst Joseph Schwartz has reiterated their neutral stance on PTCT stock, giving a Hold rating on October 8. Joseph Schwartz has ...

Maintain Position on PTC Therapeutics Amidst Uncertainties and NDA Delay: Schwartz's Hold Rating

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price ta...

Morgan Stanley Remains a Hold on PTC Therapeutics (PTCT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nurix Therapeutics (NRIX – Research Report) and PTC Therapeutics ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and PTC Therapeutics (PTCT)

PTC Therapeutics ( ($PTCT) ) has provided an announcement. PTC Therapeutics announced that the European Medicines Agency's Committee for Medicinal ...

PTC Therapeutics Faces Setback on Translarna Approval

CHMP maintains negative opinion on PTC Therapeutics' DMD treatment

PTC Therapeutics resubmitted NDA for Translarna accepted by FDA

ACCD

NRIX

Press Releases

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

Comments

PTC Therapeutics

PTC Therapeutics (PTCT) Opzioni

PTC Therapeutics (NASDAQ:PTCT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO